Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

Mednet Member

Medical Oncology · University of Michigan Medical School

Since my initial response to this question, the ADAURA study has been fully published (NEJM 383:1711, 2020) and the FDA has approved osimertinib as adjuvant therapy for people with resected NSCLC harboring an EGFR sensitizing mutation. However, neither of these events has altered my opinion that des...